Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Carcinogenesis ; 27(9): 1917-22, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16679309

ABSTRACT

Recent studies from our laboratory have shown the chemopreventive effects of alpha-santalol against 7,12-dimethylbenzanthracene (DMBA) initiated and 12-O-tetradecanoylphorbol-13-acetate (TPA) promoted skin tumor development in mice. The objective of the present investigation was to study the effects of alpha-santalol on ultraviolet B (UVB) radiation-induced skin tumor development and UVB-caused increase in epidermal ornithine decarboxylase (ODC) activity in female hairless SKH-1 mice. For the tumor studies, 180 mice were divided into three groups of 60 mice each, and each group was divided into two subgroups of 30 mice. The first subgroup served as control and was treated topically on the dorsal skin with acetone. The second subgroup served as experimental and was treated topically on the dorsal skin with alpha-santalol (5%, w/v in acetone). The tumorigenesis in the first group was initiated with UVB radiation and promoted with TPA; in the second group it was initiated with DMBA and promoted with UVB radiation; and in the third group it was both initiated and promoted with UVB radiation. In each case, the study was terminated at 30 weeks. Topical application of alpha-santalol significantly (P<0.05) decreased tumor incidence and multiplicity in all the three protocols, suggesting its chemopreventive efficacy against UVB radiation-caused tumor initiation, tumor promotion and complete carcinogenesis. In a short-term biochemical study, topical application of alpha-santalol also significantly (P<0.05) inhibited UVB-induced epidermal ODC activity. Together, for the first time, our findings suggest that alpha-santalol could be a potential chemopreventive agent against UVB-induced skin tumor development and, therefore, warrants further investigations.


Subject(s)
Anticarcinogenic Agents/pharmacology , Neoplasms, Radiation-Induced/prevention & control , Sesquiterpenes/pharmacology , Skin Neoplasms/chemically induced , Skin Neoplasms/prevention & control , 9,10-Dimethyl-1,2-benzanthracene , Animals , Carcinogens , Drugs, Chinese Herbal/pharmacology , Female , Mice , Mice, Hairless , Models, Chemical , Ornithine Decarboxylase/metabolism , Polycyclic Sesquiterpenes , Skin Neoplasms/etiology , Ultraviolet Rays
2.
Cancer Epidemiol Biomarkers Prev ; 12(2): 151-6, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12582025

ABSTRACT

Studies from our laboratory have indicated skin cancer chemopreventive effectsof sandalwood oil in CD-1 mice. The purpose of this investigation was to study the skin cancer chemopreventive effects of alpha-santalol, a principal component of sandalwood oil in CD-1 and SENCAR mice. alpha-Santalol was isolated from sandalwood oil by distillation under vacuum and characterized by nuclear magnetic resonance and gas chromatography-mass spectrometry. Chemopreventive effects of alpha-santalol were determined during initiation and promotion phase in female CD-1 and SENCAR mice. Carcinogenesis was initiated with 7,12-dimethylbenz(a)anthracene and promoted with 12-O-tetradecanoylphorbol-13-acetate (TPA). The effects of alpha-santalol treatment on TPA-induced epidermal ornithine decarboxylase (ODC) activity and (3)H-thymidine incorporation in epidermal DNA of CD-1 and SENCAR mice were also investigated. alpha-Santalol treatment during promotion phase delayed the papilloma development by 2 weeks in both CD-1 and SENCAR strains of mice. alpha-Santalol treatment during promotion phase significantly (P < 0.05) decreased the papilloma incidence and multiplicity when compared with control and treatment during initiation phase during 20 weeks of promotion in both CD-1 and SENCAR strains of mice. alpha-Santalol treatment resulted in a significant (P < 0.05) inhibition in TPA-induced ODC activity and incorporation of (3)H-thymidine in DNA in the epidermis of both strains of mice. alpha-Santalol significantly prevents papilloma development during promotion phase of 7,12-dimethylbenz(a)anthracene-TPA carcinogenesis protocol in both CD-1 and SENCAR mice, possibly by inhibiting TPA-induced ODC activity and DNA synthesis. alpha-Santalol could be an effective chemopreventive agent for skin cancer. Additional experimental and clinical studies are needed to investigate the chemopreventive effect of alpha-santalol in skin cancer.


Subject(s)
Papilloma/prevention & control , Plant Oils/therapeutic use , Sesquiterpenes/therapeutic use , Skin Neoplasms/prevention & control , Administration, Topical , Animals , Carcinogens/adverse effects , Chemoprevention , Disease Models, Animal , Dose-Response Relationship, Drug , Female , Incidence , Mice , Mice, Inbred SENCAR , Ornithine Decarboxylase/drug effects , Papilloma/epidemiology , Plant Oils/administration & dosage , Sesquiterpenes/administration & dosage , Skin Neoplasms/epidemiology , Tetradecanoylphorbol Acetate/adverse effects , Time Factors , Treatment Outcome , Women's Health
SELECTION OF CITATIONS
SEARCH DETAIL
...